<DOC>
	<DOCNO>NCT00671710</DOCNO>
	<brief_summary>Tumors central nervous system potentially curable . For tumor comparable histology grade , resectability important prognostic factor affect survival particularly child . However , infiltrative nature malignant cell produce indistinct border normal malignant tissue , lack easily identifiable tumor margin confound attempt toward total resection . The investigator propose identify border tumor intraoperatively use protoporphyrin fluorescence malignant cell thereby provide complete tumor resection .</brief_summary>
	<brief_title>Study Aminolevulinic Acid Enhance Visualization Resection Malignant Glial Tumors Brain</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>patient must clinically document primary brain tumor resection clinically indicate . Anticipated histology resection include : anaplastic astrocytoma , astrocytoma malignant NOS , brain stem glioma , ependymoma malignant , glioblastoma , glioblastoma multiforme , gliosarcoma , malignant oligodendroglioma , medulloblastoma , mixed astrocytomaependymoma prior therapy consideration protocol entry age unrestricted ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % , ) life expectancy consideration protocol entry patient must normal organ marrow function define : leukocyte _ &gt; 3,000/ml absolute neutrophil count _ &gt; 1,500/ml platelet &gt; _100,000/ml total bilirubin : within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) _ &lt; 2.5 X institutional upper limit normal creatinine : within normal institutional limit creatinine clearance &gt; _60 ml/min/1.73 m2 patient creatinine level institutional normal woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . ability understand willingness sign write informed consent document parent guardian ability understand willingness sign write informed consent . prior therapy exclusion criterion patient may receive investigational agent history allergic reaction attribute compound similar chemical biologic composition aminolevulinic adic ( ALA ) personal family history porphyria uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement pregnant woman exclude , breastfeed discontinue mother treated aminolevulinic acid .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>malignant glial brain tumor</keyword>
</DOC>